Search results for "PLACEBO"

showing 10 items of 704 documents

Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical …

2008

Abstract The objective of this study was to evaluate the long-term clinical benefits and safety of recombinant human arylsulfatase B (rhASB) treatment of mucopolysaccharidosis type VI (MPS VI: Maroteaux-Lamy syndrome), a lysosomal storage disease. Fifty-six patients derived from 3 clinical studies were followed in open-label extension studies for a total period of 97–260 Weeks. All patients received weekly infusions of rhASB at 1mg/kg. Efficacy was evaluated by (1) distance walked in a 12-minute walk test (12MWT) or 6-minute walk test (6MWT), (2) stairs climbed in the 3-minute stair climb (3MSC), and (3) reduction in urinary glycosaminoglycans (GAG). Safety was evaluated by compliance, adve…

AdultMaleArylsulfatase Bmedicine.medical_specialtyAdolescentN-Acetylgalactosamine-4-SulfataseEndocrinology Diabetes and MetabolismMucopolysaccharidosis type VIWalkingMotor ActivityPlaceboBiochemistryEndocrinologyInternal medicineGeneticsmedicineHumansChildAdverse effectMolecular BiologyGlycosaminoglycansMucopolysaccharidosis VIbusiness.industryMucopolysaccharidosis VIEnzyme replacement therapymedicine.diseaseRecombinant ProteinsSurgeryClinical trialMaroteaux–Lamy syndromeTreatment OutcomeChild PreschoolFemalebusinessFollow-Up StudiesMolecular Genetics and Metabolism
researchProduct

Sublingual administration of captopril in patients with acute myocardial ischemia.

1991

Summary: To investigate the anti-ischemic capability of the angiotensin-converting enzyme inhibitor captopril, 10 patients with acute myocardial ischemia (angina pectoris >1 h, ST-segment depression ±0.1 mV, no rise in creatine phosphokinase) received 25 mg captopril sublingually after being treated with an intravenous infusion of nitroglycerin (3 mg/h) and heparin (1200 IU/h) for 1 hour. A control group of 10 patients received placebo instead of captopril. Results showed a decrease of the initial ST-segment depression from 0.25±0.04 to 0.2±0.03 mV (p>0.01) with nitroglycerin for the captopril group and from 0.26±0.05 to 0.21±0.05 mV (p>0.01) for the control group. An additional decrease to…

AdultMaleCaptoprilAdministration SublingualCoronary DiseasePlaceboSublingual administrationAngina PectorisAnginaElectrocardiographyNitroglycerinHeart ratemedicineHumanscardiovascular diseasesMyocardial infarctionCreatine KinaseClinical Trials as Topicbiologybusiness.industryHemodynamicsCaptoprilGeneral MedicineMiddle Agedmedicine.diseasemedicine.anatomical_structureAnesthesiaAcute DiseaseVascular resistancebiology.proteinCreatine kinaseDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugClinical cardiology
researchProduct

Acute Alcohol Effects on Neuronal and Attentional Processing: Striatal Reward System and Inhibitory Sensory Interactions under Acute Ethanol Challenge

2004

The acute influence of ethanol on cerebral activity induces complex psycho-physiological effects that are considerably more pronounced during acute ethanol influx than during maximal blood alcohol concentration (elimination phase). Despite the psychiatric and forensic relevance of these different ethanol effects, the underlying neuronal mechanisms are still unclear. In total, 20 male healthy volunteers were investigated each with three different experimental conditions in a randomized order using an intravenous ethanol challenge (40 g bolus infusion): during influx phase, elimination phase, and under placebo condition. During and after the ethanol (or placebo) infusion, neuropsychological t…

AdultMaleCentral nervous systemSensory systemStriatumNeuropsychological TestsPlaceboRewardFluorodeoxyglucose F18Cortex (anatomy)Image Processing Computer-AssistedmedicineHumansAttentionSingle-Blind MethodSensory cortexBrain ChemistryNeuronsPharmacologyTemporal cortexEthanolCentral Nervous System DepressantsReciprocal inhibitionNeostriatumPsychiatry and Mental healthGlucosemedicine.anatomical_structurePsychologyNeuroscienceTomography Emission-ComputedNeuropsychopharmacology
researchProduct

Sulodexide and the microcirculatory component in microphlebopathies.

1992

A double-blind, placebo-controlled study was carried out in 36 patients, aged 30 to 50 years, to evaluate the effectiveness of oral sulodexide in the treatment of chronic venous insufficiency due to idiopathic varices. Patients were allocated at random to receive either oral sulodexide as 2 capsules (each containing 250 lipoproteinolipase releasing units) twice daily or 2 identical placebo capsules twice daily over a period of 45 days. Using strain gauge plethysmographic data, assessments were made of the microcirculatory effects of treatment by calculating the coefficient of capillary filtration from measurements made on both legs of each patient on entry and after 30 and 45 days of treatm…

AdultMaleChronic venous insufficiencymedicine.drug_classHemodynamicsAdministration OralPlaceboMicrocirculationDouble-Blind MethodmedicinePlethysmographHumansGlycosaminoglycansHypolipidemic Agentsbusiness.industryAnticoagulantGeneral MedicineMiddle Agedmedicine.diseaseSulodexidePlethysmographyVenous InsufficiencyAnesthesiaChronic DiseaseFemalebusinessVaricesCurrent medical research and opinion
researchProduct

Treatment of tension-type headache with articulatory and suboccipital soft tissue therapy: A double-blind, randomized, placebo-controlled clinical tr…

2013

This study researches the effectiveness of two manual therapy treatments focused on the suboccipital region for tension-type headache. A randomized double-blind clinical trial was conducted over a period of four weeks with a follow-up at one month. Eighty-four patients with a mean age of 39.7 years (SD 11.4) with tension-type headache were assigned to 4 groups which included the following manual therapy treatment: suboccipital soft tissue inhibition; occiput-atlas-axis global manipulation; combination of both techniques; and a control group. The primary assessment consisted of collecting socio-demographic data and headache characteristics in a one-month base period, data such as age, gender…

AdultMaleComplementary and Manual TherapySoft tissue therapymedicine.medical_specialtyAdolescentPhysical Therapy Sports Therapy and RehabilitationPlaceboDouble blindYoung AdultSex FactorsDouble-Blind MethodmedicineHumansPain ManagementTherapy Soft TissueAgedbusiness.industryTension-Type HeadacheRehabilitationAge FactorsPatient AcuitySoft tissueMiddle AgedMusculoskeletal ManipulationsSurgeryIntensity (physics)Clinical trialComplementary and alternative medicineFemaleHeadachesmedicine.symptomManual therapybusinessJournal of Bodywork and Movement Therapies
researchProduct

A Nonlinear Approach to Brain Function: Deterministic Chaos and Sleep EEG

1992

In order to perform a nonlinear dimensional analysis of the sleep electroencephalogram (EEG), we applied an algorithm proposed by Grassberger and Procaccia to calculate the correlation dimension D2 of different sleep stages under Lorazepam medication versus placebo. This correlation dimension characterizes the dynamics of the sleep EEG and it estimates the degrees of freedom of the signal under study. We demonstrate that slow-wave sleep depicts a much smaller dimensionality than light or rapid eye movement (REM) sleep, and that Lorazepam does not alter the EEG's dimensionality except in stage II and REM.

AdultMaleCorrelation dimensionRapid eye movement sleepSleep REMElectroencephalographyLorazepamHippocampusModels BiologicalPhysiology (medical)mental disordersmedicineAnimalsHumansSlow-wave sleepAuditory CortexSleep Stagesmedicine.diagnostic_testbusiness.industryBrainEye movementElectroencephalographyPattern recognitionPlacebo EffectSleep in non-human animalsElectrodes ImplantedCatsSleep StagesNeurology (clinical)Artificial intelligenceSleepbusinessPsychologyNeuroscienceCurse of dimensionalitySleep
researchProduct

Platelet aggregation, ATP release and cytoplasmic Ca2+ movement: the effects of cloricromene.

1994

A placebo-controlled, double-blind, randomized, cross-over study was performed in 24 healthy volunteers. 12 volunteers received Cloricromene (100mg gastroresistant capsules twice a day) for 7 days, the other volunteers received identical placebo capsules. Subsequently, after a 7-day wash-out period, at day 15, each subject received the other treatment. Blood samples were taken on days 1 and 15 (1st day of each treatment) as well as on days 7 and 21 (7th day of each treatment) before the morning drug administration and 2 and 4 hours later. Platelet aggregation and ATP secretion were studied in whole blood (WB) using ADP and collagen as stimulating agents. Ca2+ fluxes were studied in aequorin…

AdultMaleCytoplasmAdolescentPlatelet Aggregationchemistry.chemical_elementAdministration OralPharmacologyCalciumPlaceboAdenosine TriphosphateDouble-Blind MethodOral administrationHumansPlateletSecretionWhole bloodCalcium metabolismCross-Over StudiesChemistryChromonarHematologyMiddle AgedCrossover studyAdenosine DiphosphateAnesthesiaCalciumFemaleCollagenPlatelet Aggregation InhibitorsThrombosis research
researchProduct

Chlorhexidine alcohol base mouthrinse versus Chlorhexidine formaldehyde base mouthrinse efficacy on plaque control: Double blind, randomized clinical…

2011

Background: Chlorhexidine is well known for its antiplaque effect. However, the mouthrinse based chlorhexidine antiplaque efficiency may vary according to the formulation of the final product. The aim of the present study was to compare anti-plaque effectiveness of two commercial mouthrinses: 0.12 % Chlorhexidine alcohol base (CLX-A) versus a diluted 0.1% Chlorhexidine non-alcohol base with 0.1% of Formaldehyde (CLX-F). Material and Methods: the study was a seven day randomized, double-blind, placebo-controlled trial including 30 volunteers. At the start, all participants received a dental prophylaxis. Over 7 days experimental non-brushing period, during which subjects abstained from all fo…

AdultMaleDental PlaqueMouthwashesFormaldehydeDentistryOdontologíaAlcoholPlaceboOral hygienePlaque controllaw.inventionDouble blindYoung Adultchemistry.chemical_compoundDouble-Blind MethodRandomized controlled triallawFormaldehydeHumansMedicineGeneral Dentistrybusiness.industryChlorhexidineChlorhexidineClinical and Experimental dentistry:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludOtorhinolaryngologychemistryUNESCO::CIENCIAS MÉDICASFemaleResearch-ArticleSurgerybusinessDisinfectantsmedicine.drugMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

A double blind controlled trial comparing three treatment modalities for dentin hypersensitivity

2011

Aim: This randomized, double blind, split mouth study was aimed to compare three dentin desensitizing treatment modalities. Methods: Two hundred sixty teeth of 25 patients; each having at least 2 hypersensitive teeth in each quadrant, were included. Teeth were randomized to 4 groups: Group A treated with 2% NaF solution, Group B received GLUMA®; an aqueous solution of Hydroxy-Ethyl-Methacrylate and Glutarldehyde, (HEMA-G), Group C received iontophoresis with distilled water (placebo) and Group D was treated with NaF-iontophoresis. Pain response was evaluated on a visual analogue scale (VAS), by using tactile, air blast and cold-water stimuli at 0-day, 15-day, 1-month and 3-months interval. …

AdultMaleDentin Desensitizing AgentsVisual analogue scaleDentistryPlaceboGroup Blaw.inventionYoung AdultRandomized controlled trialDouble-Blind Methodstomatognathic systemlawmedicineDentinHumansPeriodontologyGeneral DentistryDentin Sensitivitybusiness.industryDentin SensitivityMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]medicine.anatomical_structureOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASDentin Desensitizing AgentsDentin hypersensitivitySurgeryResearch-ArticleFemalebusiness
researchProduct

Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine : a phase 2 randomised, placebo-control…

2012

Lasmiditan (COL-144) is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study. We aimed to assess the efficacy and safety of oral lasmiditan for the acute treatment of migraine.In this multicentre, double-blind, parallel-group, dose-ranging study in 43 headache centres in five European countries, patients with migraine with and without aura and who were not using prophylaxis were randomly assigned (1:1:1:1:1) to treat one moderate or severe attack at home with 50 mg, 100 mg, 200 mg, or 400 mg lasmiditan, or placebo. Study drug and placebo were sup…

AdultMaleDrug-Related Side Effects and Adverse ReactionsPyridinesPopulationMedizinAdministration OralKaplan-Meier EstimatePlacebolaw.inventionYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodPiperidinesRandomized controlled triallawHumansMedicineAdverse effecteducationAgededucation.field_of_studyDose-Response Relationship Drugbusiness.industryMiddle AgedDose-ranging studymedicine.diseaseLasmiditanSerotonin Receptor Agonists3. Good healthTreatment OutcomechemistryTolerabilityMigraine030220 oncology & carcinogenesisAnesthesiaBenzamidesFemaleNeurology (clinical)business030217 neurology & neurosurgery
researchProduct